[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"NEOK Bio, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100640517",false,"NCT07612189","A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors","A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific Antibody-Drug, Conjugate in Participants With Select Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Participants must have locally advanced or metatstatic disease in a select tumor type, for which no standard therapy is available.\n* Participants must have at least 1 measurable target lesion based on RECIST v1.1.\n* Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have adequate hematologic, hepatic, and renal function.\n* Participants should have available archived tumor tissue from their most recent biopsy.\n\nKey Exclusion Criteria:\n\n* Participant's most recent systemic anti-cancer treatment was an ADC with a topoisomerase 1-inhibitor payload component.\n* Participant with known symptomatic central nervous system (CNS) metastases or any evidence of leptomeningeal disease or evidence of unstable CNS metastases, even if asymptomatic.\n* Participants with a known history of interstitial lung disease (ILD) requiring steroid treatment, or for whom suspected ILD cannot be ruled out by imaging at screening.\n* Participants with clinically severe pulmonary compromise due to intercurrent pulmonary illness and\u002For pulmonary disorder requiring supplemental oxygen or any prior pneumonectomy.\n* Participants with a QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec.","ALL","18 Years",{"count":18,"type":19},155,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).",[25],"Locally Advanced (Unresectable) or Metastatic Solid Tumors","RECRUITING","2026-05-28",{"date":29,"type":30},"2026-06-01","ACTUAL",{"date":32,"type":30},"2026-04-22",{"date":34,"type":19},"2029-02",{"name":36,"class":37},"NEOK Bio, Inc.","INDUSTRY",8,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":46,"briefSummary":47,"conditions":48,"keywords":49,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":38},"100640013","NCT07612176","A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors","A Phase 1 Dose Escalation and Expansion Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific Antibody-Drug Conjugate, in Participants With Select, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors","Key Inclusion Criteria:\n\n* Participants must have locally advanced or metastatic disease in a select tumor type, for which no standard therapy is available.\n* Participants must have at least 1 measurable target lesion based on RECIST v1.1.\n* Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Participants must have adequate hematologic, hepatic, and renal function.\n* Participants should have available archived tumor tissue from their most recent biopsy.\n\nKey Exclusion Criteria:\n\n* Participant's most recent systemic anti-cancer treatment was an ADC with a topoisomerase 1-inhibitor payload component.\n* Participants with known symptomatic central nervous system (CNS) metastases or any evidence of leptomeningeal disease or evidence of unstable CNS metastases, even if asymptomatic.\n* Participants with a known history of interstitial lung disease (ILD) requiring steroid treatment, or for whom suspected ILD cannot be ruled out by imaging at screening.\n* Participants with clinically severe pulmonary compromise due to intercurrent pulmonary illness and\u002For pulmonary disorder requiring supplemental oxygen or any prior pneumonectomy.\n* Participants with a QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec.",{"count":18,"type":19},[22],"This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).",[25],[50,51,52,53,54,55,56,57,58,59],"Antibody-Drug Conjugate","ADC","Bispecific","B7-H3","ROR1","Locally Advanced","Unresectable","Metastatic","Solid Tumor","oncology","2026-05-21",{"date":27,"type":30},{"date":63,"type":30},"2026-04-21",{"date":65,"type":19},"2029-01",{"name":36,"class":37},""]